Decreased projections for sales by Abbott due to a drop in diagnostics, accompanied by funding reductions in the US.
Abbott Adjusts to $1 Billion Sales Loss and Lowered Tariff Impact
In a significant shift from initial expectations, Abbott, a leading healthcare company, has revised its tariff-related cost impact for 2025 to just under $200 million. This is a substantial decrease from the initial estimates that were in the "few hundred million" range. However, the company anticipates a loss of approximately $1 billion in sales this year, primarily due to factors such as tariffs, a decline in COVID-19 test sales, reduced business in China's lab market, and cuts in US foreign aid for HIV testing.
Business Segment Performance
A bright spot in Abbott's portfolio is the Medical Devices segment, which has grown by more than 13% to $5.37 billion in sales, demonstrating resilience despite tariff pressures. The Diabetes segment has also shown strong growth, exceeding 20% to reach $1.98 billion in sales, indicating solid demand and somewhat offsetting other challenges. On the other hand, the Diagnostics segment has seen a decline, with Q2 diagnostics revenue down around 1.5%. This decrease is attributed to falling COVID-19 testing demand and pricing pressures from China’s procurement policies, as well as US funding cuts for HIV testing, making Diagnostics a major drag on sales.
Strategic Moves and Forecasts
Despite absorbing over $1 billion in combined headwinds from tariffs and market challenges, Abbott still aims for 6% to 7% organic sales growth in 2025, lowering its earlier guidance of 7.5% to 8.5%. To mitigate tariffs, Abbott plans to open a new cardiovascular manufacturing facility in Georgia by 2028, a strategy aimed at reducing exposure to tariff costs by domestic production.
The Future Outlook
Tariffs remain a significant but manageable cost factor for Abbott. The company's management expects the launch of a new diabetes device sometime next year, which is expected to be a significant change in the continuous glucose monitor (CGM) market, specifically for intensive insulin users. Abbott is partnering with insulin pump companies, including Tandem, Sequel Med Tech, and Beta Bionics, to support the new sensor.
In the broader context, Abbott is navigating challenges in China's core laboratory market and reduced US foreign aid funding for HIV testing. The tariff baseline currently stands at about a 10% levy on medical devices and diagnostic tests, with additional fees depending on the country of export. Although Trump administration proposals for 200% tariffs on medicines exist, they are not expected to take effect for at least a year, providing Abbott some temporary relief.
In summary, while tariffs are a significant factor, the largest sales impacts come from reduced diagnostics demand and external funding cuts rather than tariffs alone. Growth in the Medical Devices and Diabetes segments somewhat offsets these challenges, and Abbott’s strategic investments in domestic manufacturing aim to further reduce tariff exposure over time.
- Abbott, despite absorbing over $1 billion in combined sales loss and lowered tariff impact, is still aiming for 6% to 7% organic sales growth in 2025.
- The Medical Devices segment at Abbott has grown by more than 13%, demonstrating resilience despite tariff pressures.
- Despite a decline in the Diagnostics segment, Abbott anticipates the launch of a new diabetes device next year, which is expected to be a significant change in the continuous glucose monitor market.
- AI and medtech companies such as Tandem, Sequel Med Tech, and Beta Bionics are partnering with Abbott to support the new sensor.
- News of reduced US foreign aid funding for healthcare-and-wellness initiatives like HIV testing has also negatively impacted Abbott's sales.
- Abbott is considering mitigating tariffs through strategically opening a new cardiovascular manufacturing facility in Georgia by 2028.
